Based on data from its AReSVi-006 trial, the British vaccine maker said Arexvy, compared to a placebo, led to an overall ...
Specifically, the FDA recently approved Arexvy, the world’s first vaccine to fight RSV in adults aged 60 and older. According to its manufacturer GSK, the single shot provides long-term ...
The main advantage of a kit car is that it offers a lot more scope for customization than buying a regular sports car does — for example, builders usually have a choice of engines, and can add ...
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older ...
Vaccine vials have to be able to withstand significant stress The pharmaceutical company worker stood at the top of a stairwell, holding a tiny glass vial in their hand. They held the vial out ...
GSK (NYSE:GSK) reported its RSV vaccine Arexvy elicited a robust immune response in recipients aged 18 to 49 years who were at increased risk of developing lower respiratory tract disease as a ...
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...
Emergency kits are a wide-ranging category that help prepare you for natural disasters, extended power outages, and other urgent situations. Some kits prioritize food and shelter, while others ...
GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...
With the arrival of fall also comes the arrival of respiratory illness season, a time when many are at increased risk of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback